Search

Displaying results 2191 - 2200 of 10000 in total
  1. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues. … By targeting TTR mRNA, vutrisiran reduces the serum levels of TTR.

  2. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    relapsed or refractory multiple myeloma (RRMM). … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  3. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin. … Nevertheless, because the incidence of hemostasis within a timely manner is relatively comparable between the use of thrombin alfa and the placebo treatment in patient subjects, thrombin alfa is not currently

  4. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    of the limbs as the product Beromun. … It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  5. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    Maprotiline is effective at reducing symptoms of anxiety associated with depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: MAPROTILIN-NEURAX 25 MG, MAPROTILIN-NEURAX 50 MG
  6. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin). … ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors.

  7. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    Ticlopidine is an effective inhibitor of platelet aggregation. … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.

    Categories: Metabolic Side Effects of Drugs and SubstancesProducts: TICLOPIDINA EG, TACRON TABLET 250 mg
  8. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    [L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

    Categories: Metabolic Side Effects of Drugs and SubstancesProducts: Nu-gemfibrozil Cap 300mg, Nu-gemfibrozil Tab 600mg
  9. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. … A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic

  10. Drug

    Prochlorperazine

    go.drugbank.com/drugs/DB00433
    ApprovedInvestigationalVet approved

    of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia. … Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management

    Products: Nu-prochlor Tab 5mg, Nu-prochlor Tab 10mg